Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| San Francisco General Hospital | OTHER |
| University of California, San Francisco | OTHER |
| National Institutes of Health (NIH) | NIH |
The intent of this study is to see if the rate that the body breaks down l-methamphetamine (l-MA) could be used as an accurate estimate for the rate that the body breaks down d-methamphetamine (d-MA). l-MA is sold over the counter as a nasal decongestant where as d-MA is the commonly abused form of methamphetamine.
Subjects will screen at St. Luke's Hospital in San Francisco to determine their eligibility.
Once enrolled the study will take two weeks. During the first week subjects attend daily, hour-long outpatient visits at San Francisco General Hospital. At these visits subjects will receive an oral dose of l-methamphetamine, have their vitals read, answer questionnaires and receive a blood draw.
During the second week of the study subjects are admitted to San Francisco General Hospital for a week long inpatient stay. During this stay the subject continues to receive l-methamphetamine but also receives three doses of d-methamphetamine on three separate days. In addition the subject receives blood draws, has their urine collected, and answers questionnaires.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| l-methamphetamine | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| l-methamphetamine | Drug | 5mg of l-methamphetamine per day throughout the 2 week study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Serum samples | Predose and Multiple Timepoints Post Doses | |
| Urine Samples | 24 Hour Inpatient Collection |
| Measure | Description | Time Frame |
|---|---|---|
| Questionnaries | Predose and Multiple Timepoints Post Doses |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CPMC Addiction & Pharmacology Research Laboratory (APRL) | San Francisco | California | 94110 | United States |
Not provided
| ID | Term |
|---|---|
| D015508 | Nasal Obstruction |
| ID | Term |
|---|---|
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D000402 | Airway Obstruction |
| D012131 | Respiratory Insufficiency |
Not provided
Not provided
| ID | Term |
|---|---|
| C405765 | N-myristoyl-alaninol |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| d-methamphetamine | Drug | 15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13 |
|
|
| D012120 |
| Respiration Disorders |
| D010038 | Otorhinolaryngologic Diseases |